{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:58:50Z","timestamp":1792547930030,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T00:00:00Z","timestamp":1348444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Isotretinoin is the most efficacious long\u2010lasting treatment for acne; however, some factors, including polycystic ovary syndrome (PCOS), patient age, family history, and type and number of acne lesions, may lead to treatment resistance or relapse following treatment. The aim of this study was to compare the efficacy and permanence of systemic isotretinoin (SI) in nodulocystic acne patients with and without PCOS and to evaluate the factors associated with relapse during the first and second post\u2010treatment years.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods and Materials\u2002<\/jats:bold>\n                    The study included 96 female patients with nodulocystic acne. SI 0.5\u20101 mg\/kg\/dl was given, with a total cumulative dose of 120\u2013150 mg\/kg. Response to treatment and relapse during the first and second post\u2010treatment years were evaluated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    In all, the 50 non\u2010PCOS and 46 PCOS acne patients were similar. SI was similarly efficacious in both groups. In total, eight patients relapsed during the first post\u2010treatment year, versus 16 during the second. Relapse during the first year was associated with the number of nodules at the start of treatment and the number of papulopustular lesions at the end of treatment, whereas PCOS, patient age, and the number of nodules at the start of treatment were associated relapse during the second year.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    Regardless of its association with PCOS, SI was effective in the treatment of nodulocystic acne. The factors associated with relapse during the 1\n                    <jats:sup>st<\/jats:sup>\n                    and 2\n                    <jats:sup>nd<\/jats:sup>\n                    post\u2010treatment years differed, except for the number of nodules at the start of treatment.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-4632.2012.05691.x","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T04:37:12Z","timestamp":1348461432000},"page":"371-376","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse"],"prefix":"10.1111","volume":"52","author":[{"given":"Gul Aslihan","family":"Cakir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Gulru","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysel","family":"Gurler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.5070\/D34HP8N68P"},{"key":"e_1_2_6_3_2","first-page":"1","article-title":"Polycystic ovary syndrome and acne","volume":"15","author":"Chuan SS","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098"},{"key":"e_1_2_6_5_2","first-page":"111","article-title":"Polycystic ovary syndrome: a dermatologic approach","volume":"86","author":"Gon\u00e7alves de Moura HH","year":"2011","journal-title":"An Bras Dermatol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.03.014"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018130"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000090658"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1984.tb04020.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08250.x"},{"key":"e_1_2_6_11_2","first-page":"963","article-title":"Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients","volume":"7","author":"Liu A","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.5.597"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1991.tb00683.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0110"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh530"},{"key":"e_1_2_6_16_2","first-page":"133","article-title":"Oral contraceptives and systemic lupus erythematosus: what should we advice to our patients?","volume":"35","author":"Duarte C","year":"2010","journal-title":"Acta Reumatol Port"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph7020427"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.4103\/0975-1483.71621"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2009.10.006"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000090655"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2012.05691.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2012.05691.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:27:35Z","timestamp":1697376455000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2012.05691.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,24]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/j.1365-4632.2012.05691.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2012.05691.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717984181.793495304","asserted-by":"object"}]},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,24]]},"assertion":[{"value":"2012-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}